Angelini Pharma US. Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Angelini Pharma US.'s estimated annual revenue is currently $14.1M per year.(i)
  • Angelini Pharma US.'s estimated revenue per employee is $243,000

Employee Data

  • Angelini Pharma US. has 58 Employees.(i)
  • Angelini Pharma US. grew their employee count by -5% last year.

Angelini Pharma US.'s People

NameTitleEmail/Phone
1
US Human Resources HeadReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$44.6M1501%N/AN/A
#2
$573.8M15188%N/AN/A
#3
$66.5M2248%N/AN/A
#4
$2.9M186%N/AN/A
#5
$17M70-3%N/AN/A
#6
$45.1M1521%N/AN/A
#7
$14.8M6111%N/AN/A
#8
$7.6M353%N/AN/A
#9
$5.1M27-4%N/AN/A
#10
$6.5M3011%N/AN/A
Add Company

What Is Angelini Pharma US.?

Angelini Pharma Inc. has grown to become an international leader in the healthcare field. For more than two decades, the medical community has depended on our innovative dialysis and infection control products to assure their patients receive safe, effective, and reliable medical options. Over the last few years we have become recognized as a driving force in infection control, antisepsis, and disinfection markets -- offering unique, safe, and efficient solutions that make managing and treating patients easier, faster, and less costly. Angelini Pharma Inc. pursues its mission with knowledge, skill, and a close focus on ethics. Our name has become synonymous with guaranteed quality and safety. With a team of great talent and a culture of diversity and inclusiveness, we will continue to carry on this mission.

keywords:N/A

N/A

Total Funding

58

Number of Employees

$14.1M

Revenue (est)

-5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Angelini Pharma US. News

2022-03-30 - Cenobamate (ONTOZRY®), for the Treatment of Drug-Resistant ...

Angelini Pharma is committed to helping patients in the ... Cenobamate is commercially available in the US under the trademark XCOPRI®.12.

2022-03-30 - SK life science Presents Long-term Data on Cognitive and ...

Cenobamate is approved in the United States for the treatment of ... and is marketed by Angelini Pharma under the brand name ONTOZRY®.

2022-03-22 - Looking Beyond CNS, SK Biopharm Begins First US Oncology Trial

launch cenobamate this year through partner Angelini Pharma in major European countries such as France, Italy, Switzerland and Spain;.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$13.3M584%N/A
#2
$6.8M587%N/A
#3
$12.9M59N/AN/A
#4
$17.2M5920%N/A
#5
$11.7M59-6%N/A